BMS-754807

For research use only. Not for use in humans.

目录号：S1124

CAS No. 1001350-96-4

BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。

规格

价格

库存

购买数量

5mg	RMB 1480.09	现货
10mg	RMB 2214.12	现货
50mg	RMB 6299.66	现货
200mg	RMB 16953.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的BMS-754807发表文献27篇：

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2485

PubMed: 31969334 ( click the link to review the publication )

Sci Signal, 2020, 26;13(633):eaba3176

PubMed: 32457113 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

Cell Rep, 2019, 28(12):3224-3237

PubMed: 31533043 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):619-630

PubMed: 30956007 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

Drug Deliv, 2018, 25(1):241-255

PubMed: 29334272 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Genes Dev, 2017, 31(6):553-566

PubMed: 28404630 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29099049 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )
PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述

特性

胰岛素样生长因子-1R/IR家族激酶的多重抑制剂

靶点

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	点击更多
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	点击更多

体外研究

BMS-754807 有效抑制人类多种不同组织来源的肿瘤细胞系的生长，包括间充质（尤文氏肉瘤，横纹肌肉瘤，神经母细胞瘤，和脂肪肉瘤），上皮（乳腺，肺，胰腺，结肠，和胃），和造血（多发性骨髓瘤和白血病）组织，IC50值从5 nM 到 365 nM。BMS-754807 抑制 IGF-1R-Sal 细胞和 RH41细胞增殖，IC50分别为7 nM 和5 nM。BMS-754807作用于IGF-1R-Sal, Rh41 和 Geo细胞，抑制IGF-1R磷酸化，IC50分别为13 nM, 6 nM 和 21 nM。BMS-754807作用于 IGF-1R-Sal, Rh41 和Geo细胞，抑制Akt磷酸化，IC50 分别为22 nM, 13 nM 和 16 nM。BMS-754807诱导Rh41细胞凋亡。^[1] BMS-754807作用于IGF-Sal 细胞系，抑制IGF-1R (IC50 = 13nM) 和下游靶点Akt (IC50 = 22nM) 和MAPK(IC50 = 13nM) 的磷酸化。^[2] 在儿科临床前期试验计划（PPTP）中，BMS-754807作用于23种细胞系，平均EC50值为0.62 µM。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	NF\uNYhMcW6jc3WgZZN{[Xl?			MXzpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS\|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR\|UxKD1iMUPuUUk>	MoLVNVk4PzhyMkS=
IGF-Sal	Mo\zS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?			NG\Nd\|dKSzVyPUegcm0>	NV\CR5pvOTl5N{iwNlQ>
CCRF-CEM (ALL)	NYHrV3hWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYf+OUDPxE1?	M2DZemROW09?	Mk\oTWM2OD1zLkKzPUDPxE1?	NXy5Z29GOTl7OU[yO\|I>
PC3	MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MX3+OUDPxE1?	M37GfGROW09?	NUXKUYJtUUN3ME2wMlk3PSEQvF2=	NGfySVIyQTl7NkK3Ni=>
JD	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3\ucp42KM7:TR?=	NUXWenM3TE2VTx?=	NV7Hb4h6UUN3ME2wMlM6OSEQvF2=	M1m2O\|E6QTl4Mkey
DU145	M{fTc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mn7oglUh\|ryP	NEDIdm9FVVOR	NGLqd4pKSzVyPUGuOFY2KM7:TR?=	NGGxfncyQTl7NkK3Ni=>
KAG	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHTXV2p,PSEQvF2=	NFPRdItFVVOR	MlXxTWM2OD1zLk[2OUDPxE1?	NIHPRnUyQTl7NkK3Ni=>
K-562 (CML)	NFzueoVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnnlglUh\|ryP	NVnve3BJTE2VTx?=	NVTHbXNVUUN3ME2yMlMxOiEQvF2=	NIfSXIgyQTl7NkK3Ni=>
B6-P210 (Murine ALL)	NIfCZmJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1r1Z542KM7:TR?=	NXryTHhGTE2VTx?=	MlTzTWM2OD1zLkK5N{DPxE1?	NUHvcGRnOTl7OU[yO\|I>
LN CAP-FGC	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Ml\tglUh\|ryP	MUfEUXNQ	NXHLZmQzUUN3ME2xMlQ{PCEQvF2=	NILYcnMyQTl7NkK3Ni=>
VW	NFvFVXZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml\PglUh\|ryP	MYrEUXNQ	M2PPTmlEPTB;MD6wNVkh\|ryP	M3;zblE6QTl4Mkey
MV411 (B Myelomonocytic)	MnjWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NE\SVXB,PSEQvF2=	NI\3PW5FVVOR	NU\ROJpXUUN3ME2wMlM{KM7:TR?=	MmjaNVk6QTZ{N{K=
MDA-PCa-2b	NX;vUFlxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1v5T542KM7:TR?=	M2ftNGROW09?	MnHsTWM2OD1yLkC5PEDPxE1?	MmKxNVk6QTZ{N{K=
LG	MoD5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGTRfYd,PSEQvF2=	MXXEUXNQ	NVm3VlhEUUN3ME2wMlA{QCEQvF2=	M3vDTlE6QTl4Mkey
RS411 (B cell precursor-ALL)	M4nhPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVPzXmxQhjVizszN	NXO3eYk4TE2VTx?=	MoHETWM2OD1yLkGwNkDPxE1?	M1e2VFE6QTl4Mkey
22-r-1	M4\QcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mo\CglUh\|ryP	M3;idmROW09?	NHT5[JFKSzVyPUCuNVc2KM7:TR?=	NIj5dY0yQTl7NkK3Ni=>
5838	MkGyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXf+OUDPxE1?	NVyxbI5jTE2VTx?=	MlLwTWM2OD1yLkCzOEDPxE1?	MmDQNVk6QTZ{N{K=
P388 (Murine)	NIHsO5pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mlz4glUh\|ryP	MWrEUXNQ	MmThTWM2OD12LkK3JO69VQ>?	M3K4PFE6QTl4Mkey
A2780/S	MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYj+OUDPxE1?	MYnEUXNQ	MUXJR\|UxRTBwMUKyJO69VQ>?	Moi0NVk6QTZ{N{K=
RDES	M2rEXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2rDOJ42KM7:TR?=	NV;VXIh[TE2VTx?=	NVPsPJpCUUN3ME2wMlAyOiEQvF2=	MYWxPVk6PjJ5Mh?=
B6-T315I (Murine B-ALL)	NIq2VnlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUT+OUDPxE1?	NVTVNmJMTE2VTx?=	MoW0TWM2OD1{LkizJO69VQ>?	MnnzNVk6QTZ{N{K=
TOV 112D	NEHrO4ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlfQglUh\|ryP	MnLvSG1UVw>?	MXvJR\|UxRTJwMUS2JO69VQ>?	M2\yd\|E6QTl4Mkey
TC32	M1rCV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1LFdZ42KM7:TR?=	MXTEUXNQ	MoPsTWM2OD1yLkCwPEDPxE1?	M4LNdlE6QTl4Mkey
HL60 (acute myelocytic)	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoPuglUh\|ryP	NE\sRVZFVVOR	NFfNfWRKSzVyPUCuNVIh\|ryP	Mnn5NVk6QTZ{N{K=
TOV 21G	NEPRTlVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnXtglUh\|ryP	MYDEUXNQ	NFfNfpBKSzVyPUSuNlc6KM7:TR?=	Mom0NVk6QTZ{N{K=
TC71	MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1jhbZ42KM7:TR?=	M3O3NGROW09?	NXjmbXdmUUN3ME2wMlAyPCEQvF2=	NELHPG0yQTl7NkK3Ni=>
HPN-ALL (T-cell)	NWS0UFdqT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmLkglUh\|ryP	MoXPSG1UVw>?	MUTJR\|UxRTBwNUKg{txO	MVGxPVk6PjJ5Mh?=
A2780R	MlHyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYXKW2xlhjVizszN	Mln0SG1UVw>?	MWHJR\|UxRTFwNU[0JO69VQ>?	NVuwVGdGOTl7OU[yO\|I>
Rh1	Mn[zS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFn2SVl,PSEQvF2=	NEHPTmZFVVOR	MlX3TWM2OD1yLkCyO{DPxE1?	MXexPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid)	M1P6NWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYTqXmRRhjVizszN	NIDjbmxFVVOR	NFnxfllKSzVyPUCuNVYh\|ryP	NVLOTFBwOTl7OU[yO\|I>
sk-ov-3	Ml7pS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX;+OUDPxE1?	MlW3SG1UVw>?	MonETWM2OD13LkGg{txO	MmXUNVk6QTZ{N{K=
ME	M2HHSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXLETlNlhjVizszN	M3HTS2ROW09?	M4jOfWlEPTB;MD6wNVUh\|ryP	NYHDPW1sOTl7OU[yO\|I>
L1210 (Murine lymphocytic)	M4\JeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1r3UJ42KM7:TR?=	NH7BUpZFVVOR	M3PCO2lEPTB;Mj6zPUDPxE1?	NFHPUVgyQTl7NkK3Ni=>
sw-626	NEnz[m9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlfLglUh\|ryP	MX\EUXNQ	M2\6UWlEPTB;Mj6zNFYh\|ryP	NYfkV2hVOTl7OU[yO\|I>
CTR	NGnvbItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYP+OUDPxE1?	M4O2NmROW09?	M1:wXWlEPTB;MD6yOVMh\|ryP	M{C3OVE6QTl4Mkey
ML2 (Myelomonocytic)	M1LNemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoD6glUh\|ryP	NEfuV41FVVOR	NIfTfnlKSzVyPUCuNFkh\|ryP	MofwNVk6QTZ{N{K=
ovcar-3	MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NX\U[IRKhjVizszN	Mn;iSG1UVw>?	M2XIdmlEPTB;NTFOwG0>	MmDGNVk6QTZ{N{K=
Rh36	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIHqUnp,PSEQvF2=	NFjKNYdFVVOR	MlzITWM2OD1zLkSzNkDPxE1?	MljTNVk6QTZ{N{K=
MOLM-13 (acute myeloid)	MnnoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHi4N\|F,PSEQvF2=	NYXEb2Y5TE2VTx?=	NEnRfJBKSzVyPUCuOFIh\|ryP	NFXFe5UyQTl7NkK3Ni=>
ovcar-4	NGDzZYVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWL+OUDPxE1?	M36xdmROW09?	MnrBTWM2OD1zIN88US=>	MlrpNVk6QTZ{N{K=
Rh41	NX7tRWpyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1\6R542KM7:TR?=	Ml\hSG1UVw>?	MYfJR\|UxRTBwMEC1JO69VQ>?	NWPJWWhlOTl7OU[yO\|I>
Mutz 2 (acute myeloid)	NYDEcZhiT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXv+OUDPxE1?	MV;EUXNQ	NH2yWo5KSzVyPUGuNVUh\|ryP	M2O0O\|E6QTl4Mkey
ovcar-5	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoTqglUh\|ryP	NYfkcFVpTE2VTx?=	NH\mbGlKSzVyPUCuNFUh\|ryP	Mnj5NVk6QTZ{N{K=
RD1	Mo\3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUTkdlJzhjVizszN	MXXEUXNQ	MVzJR\|UxRTBwME[4JO69VQ>?	M2DBXVE6QTl4Mkey
OCI-AML 2 (acute myeloid)	MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2nWRZ42KM7:TR?=	NVvCVVhQTE2VTx?=	MnTnTWM2OD1\|LkOzJO69VQ>?	MoLuNVk6QTZ{N{K=
786-O	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVjHeXg6hjVizszN	NF\SOVBFVVOR	MoO2TWM2OD1zLk[0O{DPxE1?	NIPHSJkyQTl7NkK3Ni=>
A673	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{PXWZ42KM7:TR?=	MmDxSG1UVw>?	MlPDTWM2OD1yLkSwPEDPxE1?	NYDDUZJGOTl7OU[yO\|I>
TALL-1 (T-cell)	NXLnOW1NT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEPp[XB,PSEQvF2=	NWL3cWZzTE2VTx?=	NIP6c5JKSzVyPUGuNlgh\|ryP	MmezNVk6QTZ{N{K=
151-B	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mn;WglUh\|ryP	MUnEUXNQ	NIHtUFhKSzVyPUKuOlch\|ryP	MXqxPVk6PjJ5Mh?=
PFSK-1	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVf+OUDPxE1?	M37SbGROW09?	M2jkcmlEPTB;MD6xN\|Ih\|ryP	NHvJfmQyQTl7NkK3Ni=>
THP-1	M1;aeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3;XZp42KM7:TR?=	NYXDPXpiTE2VTx?=	NFqzcoNKSzVyPU[uOVgh\|ryP	MXixPVk6PjJ5Mh?=
HEK293	NX35U\|JmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M33kT542KM7:TR?=	MlHLSG1UVw>?	MXHJR\|UxRTBwOUG1JO69VQ>?	MnS3NVk6QTZ{N{K=
DAOY	MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlPNglUh\|ryP	NWrRZppbTE2VTx?=	MnOzTWM2OD1zLkm3PUDPxE1?	NWe2WIc1OTl7OU[yO\|I>
SET2	M2WxNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYTHfZBJhjVizszN	NF;UfFNFVVOR	MYDJR\|UxRTBwMkm4JO69VQ>?	MnTDNVk6QTZ{N{K=
HTB-46	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MY\+OUDPxE1?	NEHUXXRFVVOR	MkG0TWM2OD13LkK1JO69VQ>?	NWnRWm02OTl7OU[yO\|I>
SK-NAS	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NY[5fpZ3hjVizszN	NHfCVVhFVVOR	MnW0TWM2OD1yLkS5O{DPxE1?	NH3aWFAyQTl7NkK3Ni=>
CTLL2	NG\WTXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVT+OUDPxE1?	NWPjTmZXTE2VTx?=	MVXJR\|UxRjFwMECg{txO	NVH5bXl4OTl7OU[yO\|I>
HTB-47	M4XnW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXr+OUDPxE1?	M{[3PWROW09?	M2LVXGlEPTB;Mj6wOVYh\|ryP	NUXac2ZNOTl7OU[yO\|I>
LAN-1	MoTPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFL0dJF,PSEQvF2=	NUjDcIlbTE2VTx?=	M4naWWlEPTB;MD6wOEDPxE1?	MnzINVk6QTZ{N{K=
ST486	NYrQepVCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUT+OUDPxE1?	MUHEUXNQ	NEfBN3pKSzVyPUGuNVkh\|ryP	NFG4[VQyQTl7NkK3Ni=>
HS766T	NEfnUYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUfvOYVyhjVizszN	NEHuSVdFVVOR	M3zvfmlEPTB;Mj6wNFEh\|ryP	NYrBWmxJOTl7OU[yO\|I>
IMR-32	NYn0PWZMT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXj+OUDPxE1?	NWfZcXFDTE2VTx?=	NGHMVIdKSzVyPUCuNlYyKM7:TR?=	MkO5NVk6QTZ{N{K=
Daudi (Burkitt's)	M4Xad2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{n1VZ42KM7:TR?=	NFe5UIpFVVOR	MU\JR\|UxRTJwNkO3JO69VQ>?	NX3URZdQOTl7OU[yO\|I>
Aspc-1	MoLBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIXvTll,PSEQvF2=	M4\tZWROW09?	MYfJR\|UxRTBwM{e5JO69VQ>?	NYniOVZoOTl7OU[yO\|I>
SK-NSH	MmTtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYL+OUDPxE1?	NHHsSJZFVVOR	M{G4OmlEPTB;MD6xN\|kh\|ryP	NH\3V\|QyQTl7NkK3Ni=>
MEC-1 (Chronic B cell)	NV7HRXR3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH:yb\|F,PSEQvF2=	NWXESlVLTE2VTx?=	MYrJR\|UxRTJwNkO3JO69VQ>?	NFvibFEyQTl7NkK3Ni=>
Capan-2	NVHtNIE5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH;qXIF,PSEQvF2=	NE\6RnVFVVOR	NILWWJZKSzVyPUGuO\|c1KM7:TR?=	MknuNVk6QTZ{N{K=
SHSY5Y	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVjQSYpnhjVizszN	MoT4SG1UVw>?	Mn70TWM2OD1yLkGwOkDPxE1?	MnvUNVk6QTZ{N{K=
U937 (Histioocytic)	NIPQNJBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVP+OUDPxE1?	NH33fmRFVVOR	MULJR\|UxRjVwMECg{txO	NXT5dYc2OTl7OU[yO\|I>
Bxpc-1	NHf6SldIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVOwbJpShjVizszN	NGrDNYZFVVOR	M1XTWWlEPTB;MT65NlQh\|ryP	NF7XdJcyQTl7NkK3Ni=>
Bxpc-3	NF\iUFdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmfqglUh\|ryP	NFrObYJFVVOR	M3q4[2lEPTB-NT6wNEDPxE1?	MnjzNVk6QTZ{N{K=
HTB-92	M2Xqb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlvKglUh\|ryP	MXXEUXNQ	M4TtO2lEPTB;MT6wNkDPxE1?	NIrmb3EyQTl7NkK3Ni=>
OCI-LY10 (B-cell)	NWjOTHd3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX\+OUDPxE1?	NUPYZmV7TE2VTx?=	NWrtWoF1UUN3ME2wMlQ2KM7:TR?=	M4PaSFE6QTl4Mkey
PANC-1	MoTxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2LBN542KM7:TR?=	NFXoWIZFVVOR	NU\NVotyUUN3ME61MlAxKM7:TR?=	NHXGO20yQTl7NkK3Ni=>
To184.T	M1XEV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWfUZYVwhjVizszN	NWPQXI1ZTE2VTx?=	MYjJR\|UxRTBwNE[5JO69VQ>?	MYmxPVk6PjJ5Mh?=
OCI-LY19 (B-cell)	NYK0SnFHT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Ml;HglUh\|ryP	NH;T[ZhFVVOR	MkLpTWM2OD1yLkSg{txO	NG\zd2oyQTl7NkK3Ni=>
PANC-1 BM	NGS3SIVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXj+OUDPxE1?	MUDEUXNQ	MoLCTWM2OD53LkCwJO69VQ>?	NVO2dm4xOTl7OU[yO\|I>
SA-4	M37Idmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWL+OUDPxE1?	MmHUSG1UVw>?	M3XhXmlEPTB;MT6zNFEh\|ryP	NIOwPVQyQTl7NkK3Ni=>
RPMI 8226	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUOzeJFXhjVizszN	MW\EUXNQ	MVPJR\|UxRTFwMkmzJO69VQ>?	MlO4NVk6QTZ{N{K=
HPAF-II	NXjuS\|d6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYn+OUDPxE1?	M1HhOWROW09?	NFnEPYhKSzVyPUCuOlQ1KM7:TR?=	MkjONVk6QTZ{N{K=
SHP-77	NHrrVolIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWm4[3JthjVizszN	MnHXSG1UVw>?	NHzZbG1KSzVyPUGuPFg5KM7:TR?=	MoPwNVk6QTZ{N{K=
U266 B1	NV7G[WV5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFPSOFB,PSEQvF2=	NVvnWG9MTE2VTx?=	M{LwdmlEPTB;MT62Olkh\|ryP	M4\vSlE6QTl4Mkey
Hs700t	NHHkcGhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnvJglUh\|ryP	Mn;ZSG1UVw>?	M4jhXWlEPTB;MD6yN\|Eh\|ryP	NEfWZnAyQTl7NkK3Ni=>
NCI-446	Mn\vS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX7hdZVMhjVizszN	NFztfHFFVVOR	NXXIdYpHUUN3ME2xMlE2PCEQvF2=	NGnFUGYyQTl7NkK3Ni=>
H929	MVTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWH+OUDPxE1?	MXXEUXNQ	M2TXWGlEPTB;MD6wNVQh\|ryP	M3;6flE6QTl4Mkey
PL45	MlPFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmHvglUh\|ryP	NUPuboRNTE2VTx?=	MlfRTWM2OD1{LkK1OUDPxE1?	MkLxNVk6QTZ{N{K=
NCI-H383	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnriglUh\|ryP	NXfPTItjTE2VTx?=	NVrUSFlWUUN3ME61MlAxKM7:TR?=	MWOxPVk6PjJ5Mh?=
JJN3	NGnwTpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVr+OUDPxE1?	MYjEUXNQ	NFHrXpVKSzVyPUKuOFM{KM7:TR?=	NX;MRVFnOTl7OU[yO\|I>
SU.86.86	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVP+OUDPxE1?	MmfTSG1UVw>?	MlHaTWM2OD1{Lk[3NkDPxE1?	M3;6RlE6QTl4Mkey
H1299	NXL0PWEyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnG2glUh\|ryP	MlTzSG1UVw>?	MWnJR\|UxRjVwMECg{txO	MmDqNVk6QTZ{N{K=
MDA-MB-468	NXvDOVlWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXTkO2hQhjVizszN	M361eWROW09?	M{iweWlEPTB;MD61NFQh\|ryP	M3j6VFE6QTl4Mkey
SW1990	Ml\FS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MV3+OUDPxE1?	NV:5NosyTE2VTx?=	NHvHUWJKSzVyPUCuPFI3KM7:TR?=	Mo[zNVk6QTZ{N{K=
Calu-6	NFW5RmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MX7+OUDPxE1?	M3HVemROW09?	MkDGTWM2OD53LkCwJO69VQ>?	NEGxOIIyQTl7NkK3Ni=>
MDA-MB-231	NV3PblZ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmjMglUh\|ryP	MoX5SG1UVw>?	NE\MR3BKSzVyPUGuOlQ5KM7:TR?=	MYGxPVk6PjJ5Mh?=
SW-684	MlX2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFnHWmt,PSEQvF2=	MX7EUXNQ	MV7JR\|UxRjVwMECg{txO	NV;NZXhUOTl7OU[yO\|I>
H209	M{PUemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mo\pglUh\|ryP	NY\jeYVpTE2VTx?=	M2ezUmlEPTB;MT6xPVMh\|ryP	NYe3RWVOOTl7OU[yO\|I>
MDA-MB-231T	Mn;QS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1;1T542KM7:TR?=	NGPmV4tFVVOR	NYfpfmp5UUN3ME61MlAxKM7:TR?=	NILWOoIyQTl7NkK3Ni=>
HT1080/S	NIPpc3NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFzPV2l,PSEQvF2=	NUXNU3R3TE2VTx?=	MWrJR\|UxRTBwNUOxJO69VQ>?	MXSxPVk6PjJ5Mh?=
H526 0.044	MmDHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGnOSll,PSEQvF2=	MnPHSG1UVw>?	NYLYV\|VEUUN3ME2wMlA1PCEQvF2=	NULsOVRmOTl7OU[yO\|I>
DU4475 2.431	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFLrV3h,PSEQvF2=	NH\sZo1FVVOR	NH6w[ZhKSzVyPUKuOFMyKM7:TR?=	M2PYW\|E6QTl4Mkey
HCT116	MnrFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2DISJ42KM7:TR?=	NYLEXXRwTE2VTx?=	MVfJR\|UxRTBwOEWyJO69VQ>?	Ml74NVk6QTZ{N{K=
M109	M2TUS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoXhglUh\|ryP	M4\EPGROW09?	M2jyTWlEPTB;MT6wOVUh\|ryP	MUCxPVk6PjJ5Mh?=
BT549	M1jEXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVj+OUDPxE1?	NGnQRXVFVVOR	MYrJR\|UxRTFwNkS1JO69VQ>?	NUPsTmRWOTl7OU[yO\|I>
HCT116/VM46	NX:5c2FUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3m2[p42KM7:TR?=	MXXEUXNQ	NFHRempKSzVyPUGuO\|AzKM7:TR?=	NWe0XYl{OTl7OU[yO\|I>
H460	Mo\PS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVnC[ZhGhjVizszN	NXPC[5lnTE2VTx?=	M1n2O2lEPTB;MD63PVUh\|ryP	Ml7tNVk6QTZ{N{K=
MCF-7	M1HJNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnfEglUh\|ryP	NUjBcnZ7TE2VTx?=	MYjJR\|UxRTBwMEG2JO69VQ>?	MoG3NVk6QTZ{N{K=
GEO	MkHkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MojtglUh\|ryP	MnHHSG1UVw>?	MY\JR\|UxRTBwM{W2JO69VQ>?	NH6yTGIyQTl7NkK3Ni=>
H441 0.646	M1O0[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVP+OUDPxE1?	M1vIcmROW09?	NULzUZZEUUN3ME2wMlY1PiEQvF2=	MV2xPVk6PjJ5Mh?=
MCF-7-807R	NVLiXldnT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NU\w[ZRKhjVizszN	MVfEUXNQ	NFTZXYdKSzVyPUCuOFkh\|ryP	NXPK[WR6OTl7OU[yO\|I>
Colo205	Ml7RS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NV\zVZk5hjVizszN	MmTqSG1UVw>?	NILlboJKSzVyPUCuNVA1KM7:TR?=	NFv1WVcyQTl7NkK3Ni=>
H292	NIjyTIpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVTCbnV3hjVizszN	MofiSG1UVw>?	MWfJR\|UxRTBwN{i4JO69VQ>?	Mn3XNVk6QTZ{N{K=
BT474 (S)	NYq1No5FT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MkPqglUh\|ryP	NWrIXHFLTE2VTx?=	MUjJR\|UxRTJwNECzJO69VQ>?	MXOxPVk6PjJ5Mh?=
HT-29	M1XkVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkPrglUh\|ryP	NUPwVWlYTE2VTx?=	NYDLNnhtUUN3ME2yMlExOyEQvF2=	NWD0bm5LOTl7OU[yO\|I>
A549	MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2[yfJ42KM7:TR?=	M{DFemROW09?	M2DHT2lEPTB;MD62O\|Uh\|ryP	NH7TbpAyQTl7NkK3Ni=>
BT474-M1	M13udGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYPpfHJYhjVizszN	MWDEUXNQ	Mnq5TWM2OD1{LkO2OUDPxE1?	NXmz[5N4OTl7OU[yO\|I>
SW480	MmXmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Ml[5glUh\|ryP	NUDVXXJsTE2VTx?=	MUDJR\|UxRjVwMECg{txO	NFznTm4yQTl7NkK3Ni=>
L2987	M1TBT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MonGglUh\|ryP	MXLEUXNQ	M4PSfmlEPTB;MD60OFIh\|ryP	NGKzPWoyQTl7NkK3Ni=>
AU565	NEfxRWxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmjaglUh\|ryP	NGDsVHpFVVOR	M360cWlEPTB;ND65O{DPxE1?	M1XOTFE6QTl4Mkey
SW403	M2TNWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUf+OUDPxE1?	NH7mRZJFVVOR	M1fmTmlEPTB;MD6yNkDPxE1?	NF3uXoUyQTl7NkK3Ni=>
H1437	Ml7yS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVXWNolphjVizszN	NVHqTZl[TE2VTx?=	MVTJR\|UxRTBwNUKzJO69VQ>?	MV2xPVk6PjJ5Mh?=
BT-20	NYnlR45RT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3rLeZ42KM7:TR?=	NY\Uc\|luTE2VTx?=	M1nWeWlEPTB;Mz61OlIh\|ryP	MUmxPVk6PjJ5Mh?=
Colo320HSR	NVTJbGZ7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYD+OUDPxE1?	M4\TdmROW09?	M1K2ZmlEPTB;MD6wNVEh\|ryP	NIjCZYcyQTl7NkK3Ni=>
H2087	MnvOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3vsdZ42KM7:TR?=	MWPEUXNQ	MkHWTWM2OD5zLkCwJO69VQ>?	M4rkfFE6QTl4Mkey
HCC1419	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2fEWZ42KM7:TR?=	NYfIe2FYTE2VTx?=	MV7JR\|UxRTJwNUG3JO69VQ>?	MljlNVk6QTZ{N{K=
WiDr	MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NH\NfI9,PSEQvF2=	MnXkSG1UVw>?	M2GzSWlEPTB;MD6wO\|Yh\|ryP	MXGxPVk6PjJ5Mh?=
H661 0.573	NGHDV\|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXHKTHE5hjVizszN	NHjSR2tFVVOR	NF7ZOIhKSzVyPUCuOVc{KM7:TR?=	M{K5XFE6QTl4Mkey
HCC-38	NETDTVhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkPiglUh\|ryP	NVGwflRmTE2VTx?=	NV3scIdKUUN3ME61MlAxKM7:TR?=	M17JNlE6QTl4Mkey
LS174T	M4\1Smdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUf+OUDPxE1?	M3;nZWROW09?	MV7JR\|UxRTBwNUO1JO69VQ>?	NWDGUoRCOTl7OU[yO\|I>
H211	M4T0cGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M33Fep42KM7:TR?=	NF;DT2ZFVVOR	NE\2bJZKSzVyPUCuO\|M{KM7:TR?=	MVyxPVk6PjJ5Mh?=
HCC70	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnnUglUh\|ryP	NGnMVYJFVVOR	NWS5TZBPUUN3ME2xMlU2KM7:TR?=	NXTHZlV4OTl7OU[yO\|I>
SW116	M4XaOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MV\+OUDPxE1?	MUjEUXNQ	NEPxbmZKSzVyPUCuNFY4KM7:TR?=	MV:xPVk6PjJ5Mh?=
H513	NYTKPIQ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX\+OUDPxE1?	MlTXSG1UVw>?	NYDsOnplUUN3ME20MlQ1QCEQvF2=	M2TNWlE6QTl4Mkey
MDA-MB-157	M{jKZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1q1PZ42KM7:TR?=	Mo\sSG1UVw>?	NUHtXIJQUUN3ME2wMlA{PiEQvF2=	MUOxPVk6PjJ5Mh?=
H2052	MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEHoXIh,PSEQvF2=	NUnOOXdqTE2VTx?=	NF3zXHVKSzVyPUGuNFUh\|ryP	MkSxNVk6QTZ{N{K=
MDA-MB-415	M{fTfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MlfNglUh\|ryP	MU\EUXNQ	M1Lue2lEPTB-NT6wNEDPxE1?	M{XEeVE6QTl4Mkey
DLD-1	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4rTVJ42KM7:TR?=	NEC0dGdFVVOR	NFfsNWtKSzVyPUCuPVA6KM7:TR?=	Mlz3NVk6QTZ{N{K=
H2595	M1rYbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkjBglUh\|ryP	M120e2ROW09?	NYm3e2hJUUN3ME20MlQ4PSEQvF2=	MmDZNVk6QTZ{N{K=
MDA-MB-435S	NIDWV4RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3u4UJ42KM7:TR?=	NF6yeGdFVVOR	MmX4TWM2OD1zLki2PUDPxE1?	NETmUJgyQTl7NkK3Ni=>
HCT15	M132R2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NE\FcYR,PSEQvF2=	NWnvUFBTTE2VTx?=	M1\UeWlEPTB-MT6wNEDPxE1?	NW\IRnlNOTl7OU[yO\|I>
SK-Hep1	M3\COmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NX3yd\|J6hjVizszN	NY\DRnlITE2VTx?=	MmPPTWM2OD1yLkG0OkDPxE1?	NFXEWZgyQTl7NkK3Ni=>
MDA-MB-436	NFLUe\|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXL+OUDPxE1?	M3zvVWROW09?	NYTJUoY1UUN3ME21MlUxOiEQvF2=	MnL6NVk6QTZ{N{K=
KM12C	NHXBPG5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVnkUYlQhjVizszN	NVTHNnVpTE2VTx?=	NYTm[nRKUUN3ME2wMlA2PCEQvF2=	NWDNUWd1OTl7OU[yO\|I>
HEPG2	Ml\SS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWr+OUDPxE1?	MX;EUXNQ	MWjJR\|UxRTBwMEK1JO69VQ>?	NXjrc\|JuOTl7OU[yO\|I>
MDA-MB-453	Moj0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEKwV4t,PSEQvF2=	NVO1Z212TE2VTx?=	NVXjOVR4UUN3ME2xMlg3QSEQvF2=	MVqxPVk6PjJ5Mh?=
KM12SM	MWDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYXDOI9EhjVizszN	M2nrSmROW09?	M4\jTGlEPTB;MD6wOVkh\|ryP	M3;CRVE6QTl4Mkey
1483	M2XLN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3HRPZ42KM7:TR?=	M4L0PWROW09?	NH3YbJNKSzVyPUKuNVkh\|ryP	MnztNVk6QTZ{N{K=
Hs578t	NYe5e4x5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYn+OUDPxE1?	M13oU2ROW09?	NWPIOGRPUUN3ME2xMlI5PyEQvF2=	NFW4T4UyQTl7NkK3Ni=>
LS180	NILVRYdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmL0glUh\|ryP	NVqyXYhVTE2VTx?=	M2r1dGlEPTB;MD62PVYh\|ryP	Mmr3NVk6QTZ{N{K=
FaDu	NU[4OJltT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1T4Sp42KM7:TR?=	NIm4[ZFFVVOR	MUPJR\|UxRTFwMkeg{txO	NYHXfIIxOTl7OU[yO\|I>
ZR-75-1	NX3yWWVZT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MlLvglUh\|ryP	NHTzNWJFVVOR	MkLsTWM2OD1{LkC4OEDPxE1?	M3z5OVE6QTl4Mkey
LS513	MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MX3+OUDPxE1?	MYLEUXNQ	NFjHTY5KSzVyPUCuNVM2KM7:TR?=	NF\NfIQyQTl7NkK3Ni=>
Detroit.562	NVvFXG02T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2i5[p42KM7:TR?=	MYjEUXNQ	MX\JR\|UxRTFwMUSg{txO	NIjDSI4yQTl7NkK3Ni=>
ZR-75-30	NVT4Vo5QT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVnadZprhjVizszN	NHrHVm5FVVOR	M3\JR2lEPTB-NT6wNEDPxE1?	M3TlelE6QTl4Mkey
RKO-PM	NHHoUo5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEmzRVR,PSEQvF2=	NXjRbGhoTE2VTx?=	M1:ySmlEPTB;MD6yN\|Ih\|ryP	NWjsb2k5OTl7OU[yO\|I>
Cal.27	NXH0[IhsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYrIR2NZhjVizszN	MmrwSG1UVw>?	M1i0bmlEPTB;MjFOwG0>	NIfle3EyQTl7NkK3Ni=>
KPL4	M3PuVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MX;+OUDPxE1?	MXzEUXNQ	MmGxTWM2OD1zLkK1NkDPxE1?	NGS0ZlQyQTl7NkK3Ni=>
PKO-RM13	NH7kR3ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MX7+OUDPxE1?	M1vLb2ROW09?	MVPJR\|UxRTBwNEK1JO69VQ>?	NX3uZ25bOTl7OU[yO\|I>
HS.53.T	MmS4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIT3R45,PSEQvF2=	MkS5SG1UVw>?	MX7JR\|UxRTBwN{mg{txO	MXSxPVk6PjJ5Mh?=
EMT6	M3Hidmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoS2glUh\|ryP	NFXSTYVFVVOR	MnrMTWM2OD1yLkiwOkDPxE1?	M{mxRlE6QTl4Mkey
SNU-C1	M{jzR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M{njb542KM7:TR?=	NXfJc2dpTE2VTx?=	MXLJR\|UxRTBwMEC3JO69VQ>?	MUKxPVk6PjJ5Mh?=
SQCCY1	MmLUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlXqglUh\|ryP	NGm0eZdFVVOR	MULJR\|UxRTBwN{mg{txO	NUXmWGFLOTl7OU[yO\|I>
SW480	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUT+OUDPxE1?	NFPIbZdFVVOR	NHrBcINKSzVyPUCuNFM4KM7:TR?=	NUfMcJkzOTl7OU[yO\|I>
SCC9	MkPwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3;nXJ42KM7:TR?=	NGP1NWZFVVOR	M3jac2lEPTB;MD63OUDPxE1?	NIr1NIIyQTl7NkK3Ni=>
SK-LMS-1	M3PBeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVP+OUDPxE1?	NG\PfIpFVVOR	NVPYdpZ5UUN3ME2wMlY5PyEQvF2=	M4\P[lE6QTl4Mkey
SCC25	NFnkV49Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUL+OUDPxE1?	Mn34SG1UVw>?	MonqTWM2OD1yLk[4JO69VQ>?	NVjV[I5VOTl7OU[yO\|I>
U87	NXm1Z3JkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1KzO542KM7:TR?=	NYTscoR7TE2VTx?=	MYPJR\|UxRTBwOUWg{txO	M1vsSlE6QTl4Mkey
SCC15	MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUH+OUDPxE1?	NGHCZYdFVVOR	NFfFXXpKSzVyPUCuOlch\|ryP	M3Xvb\|E6QTl4Mkey
T98G	NVTZe4VUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{e5Up42KM7:TR?=	MkfQSG1UVw>?	MYrJR\|UxRTFwMkG4JO69VQ>?	MUWxPVk6PjJ5Mh?=
SCC4	MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXL+OUDPxE1?	NVWx[HNyTE2VTx?=	NYrlWItIUUN3ME2wMlY{KM7:TR?=	NFK4epEyQTl7NkK3Ni=>
U118	Mny4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2Xmcp42KM7:TR?=	M4\ncWROW09?	NGHMe4lKSzVyPUGuOlE5KM7:TR?=	NVO3SWdlOTl7OU[yO\|I>
TU167	MlrPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NY\XV4ZNhjVizszN	MkXCSG1UVw>?	NF60cVlKSzVyPUSuOVIh\|ryP	NGPCdZkyQTl7NkK3Ni=>
NCI-H727	NYXLTlVrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYX+NVDjiIsQvF2=	MV;EUXNQ	MXTJR\|UxRTR{ODDuUS=>	MmLINlA{QDV5NEe=
NCI-H720	MoH2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUT+NVDjiIsQvF2=	MX\EUXNQ	MofiTWM2OD1{Lkig{txO	NHLVS5YzODN6NUe0Oy=>
NCI-H835	NF7XNFVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXPUOmVjhjFy4pEK{txO	NXPtOVRKTE2VTx?=	MnHoTWM2OD1zIN88US=>	NGXIVI0zODN6NUe0Oy=>
NCI-H727	M4LG[WtqdmG\|ZTDhd5NigQ>?	NVr2N\|hthjFy4pEK{txO	NV\lZlAzTE2VTx?=	NFXo[GtqdmirYnn0d{Bkd26\|dHn0eZRqfmViSVfGNXIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MX6yNFM5PTd2Nx?=
RD	MoXtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYW3VlBqhjFy4pEK{txO		MYLJR\|UxRTFwMUKgxtVO	MYiyNVI6QDd2NR?=
Rh41	MlLYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUXrW\|k2hjFy4pEK{txO		MnPZTWM2OD1yLkC3JOK2VQ>?	MXSyNVI6QDd2NR?=
Rh18	NFnKV2hIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkP2glEx6oDMzszN		NYDRfIN5UUN3ME20Mlk3KML3TR?=	MUGyNVI6QDd2NR?=
Rh30	NV\EPVB1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUfaRY5LhjFy4pEK{txO		MWDJR\|UxRTBwMUmgxtVO	MYKyNVI6QDd2NR?=
BT-12	NES2ZZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmKzglEx6oDMzszN		M2HXb2lEPTB;MD63PEDDvU1?	MXeyNVI6QDd2NR?=
CHLA-266	MlO1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX7+NVDjiIsQvF2=		NIrZeFRKSzVyPUCuPFkhyrWP	NWnwfJR3OjF{OUi3OFU>
TC-71	NV74foEyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4PVVZ4yOOLCit88US=>		NXLMXVFKUUN3ME2wMlEyKML3TR?=	NVm5eoJ[OjF{OUi3OFU>
CHLA-9	MkOwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnfUglEx6oDMzszN		NGPOTWJKSzVyPUCuNVIhyrWP	NH;aT\|gzOTJ7OEe0OS=>
CHLA-10	NH3ESpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NH3lS4R,OTEkgJtOwG0>		NWLlTXJCUUN3ME2wMlYzKML3TR?=	M2rZUVIyOjl6N{S1
CHLA-258	MkfsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHLSS3p,OTEkgJtOwG0>		MkfSTWM2OD1yLkK3JOK2VQ>?	NIfpUZUzOTJ7OEe0OS=>
GBM2	MnHES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXLBblFUhjFy4pEK{txO		NWXI[XQzUUN3ME2xMlQ4KML3TR?=	MXeyNVI6QDd2NR?=
NB-1643	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{m5bZ4yOOLCit88US=>		M{LqPGlEPTB;MD6xNkDDvU1?	NFfqZpozOTJ7OEe0OS=>
NB-EBc1	M{\OT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NX;GcFhDhjFy4pEK{txO		NVi3OlhlUUN3ME2wMlM2KML3TR?=	M3\sWFIyOjl6N{S1
CHLA-90	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVOy[oFKhjFy4pEK{txO		MnftTWM2OD1yLke3JOK2VQ>?	NHHrZ\|UzOTJ7OEe0OS=>
CHLA-136	NUjScVlKT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVf+NVDjiIsQvF2=		MUjJR\|UxRTBwNUKgxtVO	NIPvV3EzOTJ7OEe0OS=>
NALM-6	NIrjd4ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYH+NVDjiIsQvF2=		NU\SUWhPUUN3ME2wMlQ6KML3TR?=	Moe0NlEzQTh5NEW=
COG-LL-317	Mlj0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NH7tbJJ,OTEkgJtOwG0>		NF\FRlRKSzVyPUGuN\|ghyrWP	MWSyNVI6QDd2NR?=
RS4;11	Ml7DS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXz1c\|kyhjFy4pEK{txO		M{WydGlEPTB;MD6zPEDDvU1?	MmP0NlEzQTh5NEW=
MOLT-4	MkLjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUP+NVDjiIsQvF2=		NWfXc4x7UUN3ME2wMlU{KML3TR?=	M3:zNVIyOjl6N{S1
CCRF-CEM	NVj5emZ7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnfJglEx6oDMzszN		M4i1XGlEPTB;MT6xN{DDvU1?	NHnreHMzOTJ7OEe0OS=>
Kasumi-1	NEXVcXlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHTkTI5,OTEkgJtOwG0>		NHPwdWdKSzVyPUGuNkDDvU1?	NF\SdZQzOTJ7OEe0OS=>
Karpas-299	NVrCS4w6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MV7+NVDjiIsQvF2=		NHPNb3FKSzVyPUGuOlQhyrWP	MkLDNlEzQTh5NEW=
Ramos-RA1	NYP3bYxJT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXm3RoEyhjFy4pEK{txO		NEDW[phKSzVyPUGuN\|EhyrWP	Mnv3NlEzQTh5NEW=
Rh30	NW\LWFBKTnWwY4Tpc44h[XO\|YYm=			MlnLbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	NHSzUJozPTl{NUO3PC=>
Rh41	NYTjSXVWTnWwY4Tpc44h[XO\|YYm=			MXHpcoR2[2W\|IHHuJIlv[3KnYYPlJI9nKFOISzDwbI9{eGixconsZZRqd25?	NImyWYozPTl{NUO3PC=>
RD	MlvVSpVv[3Srb36gZZN{[Xl?			M1O2c4lv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	MVqyOVkzPTN5OB?=
A549	MljZT4lv[XOnIHHzd4F6	M1;s[VAvPeLCit88US=>	NY\DUmlPTE2VTx?=	M33wcIlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v	NEj6b5ozPjl{OEW3PC=>
NCI-H358	NGXCdGlMcW6jc3WgZZN{[Xl?	NFXZXFAxNjYkgJtOwG0>	M1;YbGROW09?	NXfoWGFWcW6qaXLpeJMhUUeILVnSM2lTKGGldHn2ZZRqd25?	M2SyeFI3QTJ6NUe4
A549	NGPsbJNHfW6ldHnvckBie3OjeR?=	M{\mXVAvPeLCit88US=>	MVvEUXNQ	NWXNdYdr[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?=	MnPLNlY6Ojh3N{i=
NCI-H358	NVjY[GliTnWwY4Tpc44h[XO\|YYm=	MVOwMlXjiIsQvF2=	M{T4dmROW09?	M1S1cINifXOnczDhJINwdmO3coLlcpQh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHHu[EBGWkt?	NU[xWI93OjZ7Mki1O\|g>
A549	MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYq1XYk1hjFy4pEK{txO	NITjXmJFVVOR	NX\Y[pE1UUN3ME2wMlc3KM7:TR?=	NV[wUmNzOjZ7Mki1O\|g>
NCI-H358	M2TRPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHPrcXd,OTEkgJtOwG0>	MYTEUXNQ	M{LkdGlEPTB;MT6wPUDPxE1?	MkHxNlY6Ojh3N{i=
A549	NIHnXZJCeG:ydH;zbZMh[XO\|YYm=	Mn\BNE426oDMzszN	M1nnV2ROW09?	NH\VRVdqdmS3Y3XzJGFxd3C2b4Ppdy=>	NYnqOYZIOjZ7Mki1O\|g>
NCI-H358	NU\jS2g5SXCxcITvd4l{KGG\|c3H5	NES0SWExNjYkgJtOwG0>	NFrITodFVVOR	NUTFfZdncW6mdXPld{BCeG:ydH;zbZM>	M1;MfFI3QTJ6NUe4
A549	NHq1fWhHfW6ldHnvckBie3OjeR?=	NGHVTlkxNjYkgJtOwG0>	MnPESG1UVw>?	M4TQPJJm\HWlZYOge492dmRiY3zvd5Vz\Q>?	NIjvVZAzPjl{OEW3PC=>
NCI-H358	NHOyb5FHfW6ldHnvckBie3OjeR?=	NUnlZ4ZmOC534pEK{txO	NEfzN\|VFVVOR	NILCO3hz\WS3Y3XzJJdwfW6mIHPsc5N2emV?	M1[xXVI3QTJ6NUe4

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; PubMed: 26136493 Neuro Oncol (C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.	26136493
Growth inhibition assay	Cell viability; PubMed: 30754629 Molecules Response of SK-CO-1 to various drugs and drug combinations.	30754629

体内研究

BMS-754807(12.5mg/kg,口服)作用于携带 IGF-1R-Sal肿瘤的裸鼠，抑制肿瘤和血清中IGF-1R磷酸化。BMS-754807作用于一组选定的上皮(IGF-1R-Sal, GEO, 和Colo205），造血（JJN3）和间质（RD1和Rh41）移植瘤模型，抑制肿瘤生长，肿瘤生长抑制率从53％至115％不等。^[1] BMS-754807 (6.25 mg/kg) 作用于转基因的IGF-Sal肿瘤小鼠模型，完全抑制肿瘤生长，且抑制pIGF-1R 和 pAKT。BMS-754807与小鼠血浆和人类血浆的蛋白结合率分别为98.5% 和95.9%。BMS-754807 (25 mg/kg)作用于携带KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), 和 OS-1移植瘤的小鼠模型，显著抑制肿瘤。^[3]

激酶实验：^[1]	- 合并激酶抑制实验: 在体外激酶实验中使用重组人类 IGF-1受体酶测定BMS-754807，在生化实验中使用合成肽KKSRGDYMTMQIG 作为磷酸受体底物测定BMS-754807。在Ubottom 384孔板中使用 30 μL实验缓冲液 (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT)来进行酶活测定。通过结合ATP，1.5 μM 荧光标记肽底物, 酶和BMS-754807而开始反应，反应持续60分钟。加入EDTA终止反应。通过电泳分离荧光底物和磷酸化产物，然后在Caliper LabChip 3000上分析反应混合物。通过对剂量反应曲线进行非线性回归分析而获得IC50值。
细胞实验：^[1]	- 合并 Cell lines: IGF-1R-Sal, RH41 和 Geo 细胞系 Concentrations: 365 nM Incubation Time: 72 小时 Method: 细胞按最佳密度培养在RPMI + GLUTAMAX培养基中，培养基中含有有10％热灭活的胎牛血清（FBS），10mMHepes，青霉素和链霉素。BMS-754807处理细胞72小时后，通过测定³H-胸甘渗透到DNA中的程度而测评细胞增殖。结果表示为IC50。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带IGF-1R-Sal, GEO, Colo205, JJN3, RD1 或 Rh41 肿瘤的裸鼠 Dosages: 150 mg/kg Administration: 口服 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download BMS-754807 SDF

分子量	461.49
化学式	C₂₃H₂₄FN₉O
CAS号	1001350-96-4
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

选择性强的IGF-1R抑制剂

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
用于临床的IGF-1R抑制剂

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
最新的IGF-1R抑制剂

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
经典的IGF-1R抑制剂

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

研究领域

产品类型

定制您的化合物库

BMS-754807

客户使用Selleck生产的BMS-754807发表文献27篇：

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download BMS-754807 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品